{"id":"NCT03423173","sponsor":"Takeda","briefTitle":"Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-12","primaryCompletion":"2018-08-03","completion":"2019-01-14","firstPosted":"2018-02-06","resultsPosted":"2020-10-20","lastUpdate":"2020-10-20"},"enrollment":923,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Dengue Fever"],"interventions":[{"type":"BIOLOGICAL","name":"TAK-003","otherNames":["TDV"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"TDV Lot 1","type":"EXPERIMENTAL"},{"label":"TDV Lot 2","type":"EXPERIMENTAL"},{"label":"TDV Lot 3","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for dengue.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 in the Immunogenicity Subset","timeFrame":"1 month post second dose (Day 120)","effectByArm":[{"arm":"Placebo","deltaMin":5.3,"sd":null},{"arm":"TDV Lot 1","deltaMin":202.9,"sd":null},{"arm":"TDV Lot 2","deltaMin":293.8,"sd":null},{"arm":"TDV Lot 3","deltaMin":322.1,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":["40099800","37884415"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":131},"commonTop":["Injection site bruising","Injection site pruritus","Upper respiratory tract infection"]}}